Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Sisram Medical Ltd (the "**Company**") on a voluntary basis.

The Company is pleased to announce that the phase IIb clinical result on submental fat reduction (the "**Phase IIb Clinical Result**") of JS-001, a product licensed to Tianjin JuveStar Biotechnology Company Ltd (an associate company of the Company), has reached its primary endpoint. The Phase IIb Clinical Result showed that (i) on the 84th day after a single injection of JS-001, the volume of submental fat of the clinical trial participants was reduced by 15% on average; and (ii) most of the adverse effects were local (mainly affecting the area of injection) and transient. Pre-clinical and clinical studies of JS-001 both demonstrate that JS-001 can induce adipocyte decay and reduce thickness of fat layer, and therefore it can be used for body contouring.

A multi-regional phase III clinical trials (including mainland China) of JS-001 will be initiated in late 2022 to further verify its safety and efficacy.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, June 28, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as Executive Directors; Mr. Yifang WU and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.

* for identification purpose only